ClinicalTrials.Veeva

Menu
T

Tyler Retina Consultants | Tyler, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

EYP-1901
OCS-01
Dexamethasone
APL 3007
Pegcetacoplan
dexamethasone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 7 total trials
Locations recently updated

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidos...

Enrolling
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: APL-3007, pegcetacoplan (APL-2)
Other: Placebo, Syfovre

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling
Diabetic Macular Edema (DME)
Diabetic Macular Edema
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Trial sponsors

E
O
4
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems